Benjamin Kornitzer - Oct 3, 2022 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Med. & Quality Officer
Signature
/s/ Timothy Bensley, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Oct 3, 2022
Transactions value $
-$311,285
Form type
4
Date filed
10/5/2022, 05:57 PM
Previous filing
Sep 28, 2022
Next filing
Oct 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $36.3K +8.09K +77.63% $4.49* 18.5K Oct 3, 2022 Direct F1, F2
transaction AGL Common Stock Sale -$188K -8.09K -43.7% $23.17 10.4K Oct 3, 2022 Direct F1, F2, F3, F4
transaction AGL Common Stock Options Exercise $36.3K +8.09K +77.63% $4.49* 18.5K Oct 4, 2022 Direct F1, F2
transaction AGL Common Stock Sale -$196K -8.09K -43.7% $24.27 10.4K Oct 4, 2022 Direct F1, F2, F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -8.09K -2.35% $0.00 336K Oct 3, 2022 Common Stock 8.09K $4.49 Direct F6
transaction AGL Options (Rights to Buy) Options Exercise $0 -8.09K -2.41% $0.00 328K Oct 4, 2022 Common Stock 8.09K $4.49 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The total was decreased by 427 shares as reported in the Form 4 Amendment filed on September 29, 2022.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.92 to $23.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.21 to $24.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 These options were granted on January 31, 2020 and vest in four equal installments on January 31st of each of 2021, 2022, 2023, and 2024.